Cargando…

Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience

BACKGROUND: This retrospective study evaluates patient-reported outcomes in patients with multiple sclerosis (MS) spasticity who were treated with a cannabinoid oromucosal spray (Sativex®, USAN name: nabiximols) after not sufficiently responding to previous anti-spasticity medications. METHODS: Of 2...

Descripción completa

Detalles Bibliográficos
Autores principales:	D’hooghe, Marie, Willekens, Barbara, Delvaux, Valerie, D’haeseleer, Miguel, Guillaume, Daniel, Laureys, Guy, Nagels, Guy, Vanderdonckt, Patrick, Van Pesch, Vincent, Popescu, Veronica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218396/ https://www.ncbi.nlm.nih.gov/pubmed/34157999 http://dx.doi.org/10.1186/s12883-021-02246-0

Ejemplares similares

An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland who have been prescribed Sativex(®) (THC:CBD, nabiximols) oromucosal spray
por: Etges, Tilden, et al.
Publicado: (2016)

The influence of physiotherapy intervention on patients with multiple sclerosis–related spasticity treated with nabiximols (THC:CBD oromucosal spray)
por: Grimaldi, Alessandro Enrico, et al.
Publicado: (2019)

Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity
por: Patti, F, et al.
Publicado: (2016)

A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma
por: Twelves, Chris, et al.
Publicado: (2021)

Pain Modulation after Oromucosal Cannabinoid Spray (SATIVEX(®)) in Patients with Multiple Sclerosis: A Study with Quantitative Sensory Testing and Laser-Evoked Potentials
por: Turri, Mara, et al.
Publicado: (2018)

A Review of Scientific Evidence for THC:CBD Oromucosal Spray (Nabiximols) in the Management of Chronic Pain
por: Überall, Michael A
Publicado: (2020)

Definition, prevalence and predictive factors of benign multiple sclerosis
por: Reynders, Tatjana, et al.
Publicado: (2017)

Detecting neurodegenerative pathology in multiple sclerosis before irreversible brain tissue loss sets in
por: Van Schependom, Jeroen, et al.
Publicado: (2019)

Correction to: Detecting neurodegenerative pathology in multiple sclerosis before irreversible brain tissue loss sets in
por: Van Schependom, Jeroen, et al.
Publicado: (2020)

Feasibility of Real Time Internet-Based Teleconsultation in Patients With Multiple Sclerosis: Interventional Pilot Study
por: D'Haeseleer, Miguel, et al.
Publicado: (2020)

The spectral slope as a marker of excitation/inhibition ratio and cognitive functioning in multiple sclerosis
por: Akbarian, Fahimeh, et al.
Publicado: (2023)

Innovating Care in Multiple Sclerosis: Feasibility of Synchronous Internet-Based Teleconsultation for Longitudinal Clinical Monitoring
por: Sadeghi, Nima, et al.
Publicado: (2022)

Sativex in the Management of Multiple Sclerosis-Related Spasticity: Role of the Corticospinal Modulation
por: Russo, Margherita, et al.
Publicado: (2015)

Brain dysconnectivity relates to disability and cognitive impairment in multiple sclerosis
por: Sjøgård, Martin, et al.
Publicado: (2020)

The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis‐related spasticity
por: Celius, Elisabeth G., et al.
Publicado: (2018)

The Impact of Cognitive Dysfunction on Locomotor Rehabilitation Potential in Multiple Sclerosis
por: Denissen, Stijn, et al.
Publicado: (2019)

Cognitive-motor telerehabilitation in multiple sclerosis (CoMoTeMS): study protocol for a randomised controlled trial
por: Van Laethem, Delphine, et al.
Publicado: (2022)

Coronavirus disease 2019: favorable outcome in an immunosuppressed patient with multiple sclerosis
por: Devogelaere, Jens, et al.
Publicado: (2020)

Resting-state functional connectivity in multiple sclerosis patients receiving nabiximols for spasticity
por: Gajofatto, Alberto, et al.
Publicado: (2023)

Pharmacokinetics of Sativex(®) in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders
por: Fernández-Trapero, María, et al.
Publicado: (2020)

Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management
por: Decallonne, Brigitte, et al.
Publicado: (2018)

A post hoc evaluation of the shift in spasticity category in individuals with multiple sclerosis-related spasticity treated with nabiximols
por: Chisari, Clara Grazia, et al.
Publicado: (2023)

Relation between Heart Rate Variability and Disease Course in Multiple Sclerosis
por: Reynders, Tatjana, et al.
Publicado: (2019)

Signal quality as Achilles’ heel of graph theory in functional magnetic resonance imaging in multiple sclerosis
por: Baijot, Johan, et al.
Publicado: (2021)

Spatiotemporal and spectral dynamics of multi‐item working memory as revealed by the n‐back task using MEG
por: Costers, Lars, et al.
Publicado: (2020)

The role of hippocampal theta oscillations in working memory impairment in multiple sclerosis
por: Costers, Lars, et al.
Publicado: (2020)

Radial diffusivity reflects general decline rather than specific cognitive deterioration in multiple sclerosis
por: Baijot, Johan, et al.
Publicado: (2022)

Occurrence and Severity of Coronavirus Disease 2019 Are Associated With Clinical Disability Worsening in Patients With Multiple Sclerosis
por: Peeters, Gertjan, et al.
Publicado: (2023)

Cost-effectiveness of adding Sativex® spray to spasticity care in Belgium: using bootstrapping instead of Monte Carlo simulation for probabilistic sensitivity analyses
por: Oppe, Mark, et al.
Publicado: (2021)

Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis
por: Hilliard, A., et al.
Publicado: (2012)

Comparison of the Effectiveness and Tolerability of Nabiximols (THC:CBD) Oromucosal Spray versus Oral Dronabinol (THC) as Add-on Treatment for Severe Neuropathic Pain in Real-World Clinical Practice: Retrospective Analysis of the German Pain e-Registry
por: Ueberall, Michael A, et al.
Publicado: (2022)

Non‐interventional, prospective, observational study on spasticity‐associated symptom control with nabiximols as add‐on therapy in patients with multiple sclerosis spasticity in Austria
por: Guger, Michael, et al.
Publicado: (2023)

Correlation of Nabiximols Dose to Steady-State Concentrations of Cannabinoids in Urine Samples from Patients with Multiple Sclerosis
por: Birke, Rüdiger, et al.
Publicado: (2022)

Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study)
por: Messina, Silvia, et al.
Publicado: (2017)

A real‐world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: Analysis in relation to the newly described ‘spasticity‐plus syndrome’
por: Patti, Francesco, et al.
Publicado: (2022)

Increased brain atrophy and lesion load is associated with stronger lower alpha MEG power in multiple sclerosis patients
por: Van Schependom, Jeroen, et al.
Publicado: (2021)

Brain Volume Loss Can Occur at the Rate of Normal Aging in Patients with Multiple Sclerosis Who Are Free from Disease Activity
por: Temmerman, Joke, et al.
Publicado: (2022)

Oromucosal Administration of Interferon to Humans
por: Beilharz, Manfred W., et al.
Publicado: (2010)

Variability of Multiple Sclerosis Spasticity Symptoms in Response to THC:CBD Oromucosal Spray: Tracking Cases through Clinical Scales and Video Recordings
por: Flachenecker, Peter, et al.
Publicado: (2018)

Effectiveness, Safety, and Tolerability of Nabiximols Oromucosal Spray vs Typical Oral Long-Acting Opioid Analgesics in Patients with Severe Neuropathic Back Pain: Analysis of 6-Month Real-World Data from the German Pain e-Registry
por: Ueberall, Michael A, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n0l7edcj15fgbac3o76qs0nefq